RXRX — RECURSION PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1601830 ·
Last close
$3.56
Market Cap
$1.87B
52W High
$4.09
52W Low
$2.77
ADV30
23,619,282
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 6,301,000 | -6,189,000 | -128,505,000 | -117,504,000 | 1,339,522,000 | 654,473,000 | 314,753,000 |
| Dec 2025 | 35,351,000 | 21,076,000 | -108,334,000 | -108,122,000 | 1,474,130,000 | 743,294,000 | 343,265,000 |
| Sep 2025 | 4,983,000 | -9,704,000 | -172,202,000 | -162,253,000 | 1,399,526,000 | 659,836,000 | 352,578,000 |
| Jun 2025 | 19,103,000 | -1,058,000 | -176,227,000 | -171,897,000 | 1,302,355,000 | 525,110,000 | 383,209,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-320,952,000
Investing CF
$-9,939,000
Financing CF
$477,535,000
CapEx
$-7,133,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.20
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,193,506,000
Inventory
—
Receivables
$13,585,000
ST Investments
—
EBIT TTM
$-562,704,000
Pretax Income TTM
$-564,356,000
Interest Exp TTM
$1,652,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$66,408,000
EBITDA
$-501,225,984
Free Cash Flow
$-177,795,632
Enterprise Value
$1,410,345,600
Total Cash
$654,473,024
Total Debt
$72,375,000
Shares Out
524,677,865
Trailing EPS
$-1.16
Book Value
$1.93
ROE
-57.2%
ROA
-27.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 74,256,000 | -648,132,000 | -644,759,000 | 1,474,130,000 | 343,265,000 | — | -371,808,000 |
| Dec 2024 | 58,488,000 | -479,004,000 | -463,661,000 | 1,448,598,000 | 413,816,000 | — | -359,174,000 |
| Dec 2023 | 43,876,000 | -350,060,000 | -328,066,000 | 653,699,000 | 190,263,000 | — | -287,780,000 |
| Dec 2022 | 39,681,000 | -245,727,000 | -239,476,000 | 701,288,000 | 215,482,000 | — | -83,524,000 |
TTM Snapshot
Revenues TTM
$52,309,000
NetIncome TTM
$-296,732,000
OpCashFlow TTM
$0
Assets (Latest)
$1,448,598,000
Forward EPS
$-0.94
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $1.89B | $4.23 | — |
| TSHA | Taysha Gene Therapies, Inc. | $1.82B | $6.34 | — |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.95B | $23.04 | — |
| COAG | Hemab Therapeutics Holdings, Inc. | $1.78B | $38.03 | — |
| MESO | MESOBLAST LTD | $2.00B | $15.44 | — |
News headlines (Yahoo Finance, 1h cache)
Is Recursion Pharmaceuticals (RXRX) The Best Penny Stocks According to Billioanires?
2026-07-09 17:29 · Yahoo
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market
2026-07-08 21:50 · Yahoo
Recursion Pharmaceuticals (RXRX) Is Up 8.0% After Russell Index Additions Expand Its Investor Base – Has The Bull Case Changed?
2026-07-06 01:09 · Yahoo
Recursion Pharmaceuticals (RXRX) Stock Looks Fully Valued Despite AI Drug Hopes
2026-07-05 23:10 · Yahoo
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
2026-07-05 10:23 · Yahoo
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
2026-07-04 13:41 · Yahoo
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?
2026-07-03 15:34 · Yahoo
Cathie Wood Doubles Down on AI, Loads Up on Tesla, Palantir, and SpaceX
2026-07-01 13:04 · Yahoo
AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity
2026-06-30 13:38 · Yahoo
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
2026-06-30 12:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.